SBIR Phase II: Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring

SBIR 第二阶段：通过片上样品制备和监测进行生物电细胞富集、分选和回收

基本信息

批准号：
2222933
负责人：
Alexandra Hyler
金额：
$ 95.26万
依托单位：
CYTORECOVERY, INC.
依托单位国家：
美国
项目类别：
Cooperative Agreement
财政年份：
2023
资助国家：
美国
起止时间：
2023-02-15 至 2025-01-31
项目状态：
未结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=2222933&HistoricalAwards=false
关键词：
SBIR Phase II Bioelectrical Cell

项目摘要

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is a label-free, biological sample preparation and cell isolation platform for recovery of rare cells from a variety of sample inputs. Specifically, by carrying out sample preparation, manipulation, and monitoring on a single chip platform for selective cell recovery, the sample handling steps will be greatly reduced, thereby ensuring the maintenance of cell viability, improving sample consistency, and sustaining native cell behaviors. This recovered sample is essential for the development of cell-based therapies in regenerative medicine and cancer management. Personalized medicine also requires precision cell recoveries.This Small Business Technology Transfer (STTR) Phase I project will develop an electrically functional microfluidic sample manipulation platform for phenotype-selective recovery of cells, based on their biophysical attributes. Specifically, microfluidic designs will be integrated to swap cells from complex biological inputs into an optimized buffer to enable cell manipulation. Also, instrumentation will be developed for on-chip monitoring of the sample during various stages of the phenotype-selective cell recovery process. Further, a variety of sample inputs will be validated on the designed devices to ensure performance, consistency, and reliability for translation into commercial product lines.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛的影响/商业潜力是无标签，生物样品制备和细胞隔离平台，用于从各种样品输入中恢复稀有细胞。具体而言，通过在单个芯片平台上进行样品制备，操纵和监视以进行选择性细胞恢复，样本处理步骤将大大降低，从而确保维持细胞活力，提高样品一致性并维持本地细胞行为。该回收样品对于开发再生医学和癌症管理中的基于细胞的疗法至关重要。个性化医学还需要精确的细胞回收率。此小型企业技术转移（STTR）I期项目将根据其生物物理属性开发一个电力功能性的微流体样品操纵平台，用于对细胞的表型选择性恢复。具体而言，微流体设计将集成到从复杂的生物输入中将细胞交换为优化的缓冲液，以实现细胞操作。同样，在表型选择细胞恢复过程的各个阶段，将开发仪器以在片上监测样品。此外，将在设计的设备上验证各种样本输入，以确保将转换为商业产品线的性能，一致性和可靠性。该奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子优点和更广泛的影响来评估的评估值得支持的。